The presence of CD38, expressed in 7% of cases of HCL in a case series [4] but estimated to be as high as 1/3 of patients, was associated with substantially shorter time to next treatment (TTNT) with a difference of 3 or more years compared to those who were CD38 negative [17]. This evidence concerns the gene CD38 and hairy cell leukemia.